Cover Image

Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia

Proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators may attenuate PCSK9-induced low-density lipoprotein receptor (LDLR) degradation in lysosome and promote the clearance of circulating low-density lipoprotein cholesterol (LDL-C). A novel series of tetrahydroprotoberberine derivatives (T...

Full description

Saved in:

Bibliographic Details
Main Authors:	Chenglin Wu (Author), Cong Xi (Author), Junhua Tong (Author), Jing Zhao (Author), Hualiang Jiang (Author), Jiang Wang (Author), Yiping Wang (Author), Hong Liu (Author)
Format:	Book
Published:	Elsevier, 2019-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
by: Lillian Smith, et al.
Published: (2016)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022)

The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
by: Malwina Grobelna, et al.
Published: (2019)

Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
by: Rosaria Vincenza Giglio BD, PhD, et al.
Published: (2023)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017)

The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
by: Eun Ji Kim, et al.
Published: (2020)

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations
by: Fengyuan Lu, et al.
Published: (2024)

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
by: Bianca E. Suur, et al.
Published: (2022)

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review
by: Wei C. Yuet, et al.
Published: (2021)

Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels
by: Patricia Mester, et al.
Published: (2024)

Does pathological type of primary nephrotic syndrome affect serum concentrations of proprotein convertase subtilisin/kexin type 9?
by: Howayda El Shinnawy, et al.
Published: (2022)

Brazilin from Caesalpinia sappan L. as a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Pharmacophore-Based Virtual Screening, In Silico Molecular Docking, and In Vitro Studies
by: Muhammad Iqbal, et al.
Published: (2023)

Atherosclerosis and Toll-Like Receptor4 (TLR4), Lectin-Like Oxidized Low-Density Lipoprotein-1 (LOX-1), and Proprotein Convertase Subtilisin/Kexin Type9 (PCSK9)
by: Bahador Bagheri, et al.
Published: (2024)

Discovery and SAR analysis of phenylbenzo[d][1,3]dioxole-based proprotein convertase subtilisin/kexin type 9 inhibitors
by: Fahui Li, et al.
Published: (2022)

Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
by: Terrence L Trentman, et al.
Published: (2016)

Association of proprotein convertase subtilisin/kexin type 9 protein and oxidative stress indicators in women with preeclampsia: A case-control study
by: Anahita Abbasifard, et al.
Published: (2023)

Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI
by: Zhao X, et al.
Published: (2021)

Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified
by: Baum SJ, et al.
Published: (2019)

Effects of atrovastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics
by: Ali Nosrati Andevari, et al.
Published: (2021)

Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis
by: Yi-Ting Huang, et al.
Published: (2022)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016)

Inhibitory proproteinowej konwertazy subtylizyny/keksyny 9 nowym, przełomowym narzędziem terapeutycznym w leczeniu dyslipidemii = Proprotein convertase subtilisin/kexin type 9 inhibitors are a new, groundbreaking therapeutic tool in the treatment of dyslipidemia
by: Łukasz Wołowiec, et al.
Published: (2016)

Characterization of the Proprotein Convertase-Mediated Processing of Peroxidasin and Peroxidasin-like Protein
by: Hajnal A. Kovács, et al.
Published: (2021)

Embryo implantation is closely associated with dynamic expression of proprotein convertase 5/6 in the rabbit uterus
by: Li Ying, et al.
Published: (2011)

Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition
by: Hua Cai, et al.
Published: (2023)

Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque
by: Marcin Basiak, et al.
Published: (2022)

Sex difference in circulating PCSK9 and its clinical implications
by: Fang Jia, et al.
Published: (2022)

A Comprehensive Review of PCSK9 Inhibitors
by: Caroline Coppinger BS, et al.
Published: (2022)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
by: Martin Jozef Péč, et al.
Published: (2023)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
by: K. O. Shnaider, et al.
Published: (2023)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024)

PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
by: Lin Zhou, et al.
Published: (2024)

The wind of change - PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023)

Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
by: Łukasz Wołowiec, et al.
Published: (2023)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023)

PCSK9 INHIBITORS IN PERIPHERAL ARTERY DISEASE: REVIEW OF EFFICACY, SAFETY, AND OUTCOMES
by: Moiud Mohyeldin
Published: (2024)